title: [Reimbursement of new medical therapy].
abstract: Medical progress poses a new financial challenge for the German statutory health insurance. In order to assure the stability of the German statutory health insurance all services have to be economical, but on the other hand the health care system allows access to new therapy in the ambulant and in-patient sector. This article describes in detail how new therapies are reimbursed.
authors.affiliation: Ehlers, Ehlers & Partner, Rechtsanwaltssocietät, Widenmayerstr. 29, 80538, München, Deutschland.
authors.forename: A P F
authors.initials: AP
authors.lastname: Ehlers
authors.forename: A
authors.initials: A
authors.lastname: Wenke
mesh_terms: D003257:Consumer Product Safety / Q000331:legislation & jurisprudence; D003284:Contract Services / Q000191:economics / Q000331:legislation & jurisprudence; D003362:Cost-Benefit Analysis / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D005858:Germany; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D009313:National Health Programs / Q000191:economics* / Q000331:legislation & jurisprudence; D012051:Reimbursement Mechanisms / Q000191:economics* / Q000331:legislation & jurisprudence; D035703:Therapies, Investigational / Q000191:economics*
chemical_list: D015507:Drugs, Investigational